title: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
abstract: BACKGROUND
  Despite the introduction of the parenteral iron chelator desferrioxamine more than 30 years ago, 50% of patients with thalassaemia major die before the age of 35 years, predominantly from iron-induced heart failure. The only alternative treatment is oral deferiprone, but its long-term efficacy on myocardial iron concentrations is unknown.
  
  
  METHODS
  We compared myocardial iron content and cardiac function in 15 patients receiving long-term deferiprone treatment with 30 matched thalassaemia major controls who were on long-term treatment with desferrioxamine. Myocardial iron concentrations were measured by a new magnetic-resonance T2* technique, which shows values inversely related to tissue iron concentration.
  
  
  RESULTS
  The deferiprone group had significantly less myocardial iron (median 34.0 ms vs 11.4 ms, p=0.02) and higher ejection fractions (mean 70% [SD 6.5] vs 63% [6.9], p=0.004) than the desferrioxamine controls. Excess myocardial iron (T2* <20 ms) was less common in the deferiprone group than in the desferrioxamine controls (four [27%] vs 20 [67%], p=0.025), as was severe (T2* <10 ms) iron overload (one [7%] vs 11 [37%], p=0.04). The odds ratio for excess myocardial iron in the desferrioxamine controls versus the deferiprone group was 5.5 (95% CI 1.2-28.8).
  
  
  CONCLUSIONS
  Conventional chelation treatment with subcutaneous desferrioxamine does not prevent excess cardiac iron deposition in two-thirds of patients with thalassaemia major, placing them at risk of heart failure and its complications. Oral deferiprone is more effective than desferrioxamine in removal of myocardial iron.
authors.affiliation: Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London SW3 6NP, UK.
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Anderson
authors.forename: Beatrix
authors.initials: B
authors.lastname: Wonke
authors.forename: Emma
authors.initials: E
authors.lastname: Prescott
authors.forename: Sally
authors.initials: S
authors.lastname: Holden
authors.forename: J Malcolm
authors.initials: JM
authors.lastname: Walker
authors.forename: Dudley J
authors.initials: DJ
authors.lastname: Pennell
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000077543:Deferiprone; D003676:Deferoxamine / Q000008:administration & dosage*; D004452:Echocardiography; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D011728:Pyridones / Q000008:administration & dosage*; D016276:Ventricular Function / Q000502:physiology*; D017086:beta-Thalassemia / Q000188:drug therapy*
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine